All Wales Medicines Strategy Group Final Appraisal Report - Raltegravir (Isentress) in combination with other antiretroviral medicinal products for the treatment of human immunodeficiency virus (HIV-1) infection in treatment-experienced adult patients with evidence of HIV-1 replication despite ongoing antiretroviral therapy.

D. Hughes; D.A. Hughes; [No Value] All Wales Strategy Group.

All Wales Medicines Strategy Group Final Appraisal Report - Raltegravir (Isentress) in combination with other antiretroviral medicinal products for the treatment of human immunodeficiency virus (HIV-1) infection in treatment-experienced adult patients with evidence of HIV-1 replication despite ongoing antiretroviral therapy.

D. Hughes
, D.A. Hughes
, [No Value] All Wales Strategy Group.

NHS Wales

Research output: Book/Report › Commissioned report

Original language	English
Publisher	Unknown
Commissioning body	NHS Wales
Edition	2008
Publication status	Published - 1 Jan 2008

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

SDG 3 Good Health and Well-being

Cite this

Hughes, D., Hughes, D. A., & All Wales Strategy Group., N. V. (2008). All Wales Medicines Strategy Group Final Appraisal Report - Raltegravir (Isentress) in combination with other antiretroviral medicinal products for the treatment of human immunodeficiency virus (HIV-1) infection in treatment-experienced adult patients with evidence of HIV-1 replication despite ongoing antiretroviral therapy. (2008 ed.) Unknown.

Hughes, D. ; Hughes, D.A. ; All Wales Strategy Group., [No Value]. / All Wales Medicines Strategy Group Final Appraisal Report - Raltegravir (Isentress) in combination with other antiretroviral medicinal products for the treatment of human immunodeficiency virus (HIV-1) infection in treatment-experienced adult patients with evidence of HIV-1 replication despite ongoing antiretroviral therapy. 2008 ed. Unknown, 2008.

@book{6fd3adfc2c78489f812c58f86e2ec827,

title = "All Wales Medicines Strategy Group Final Appraisal Report - Raltegravir (Isentress) in combination with other antiretroviral medicinal products for the treatment of human immunodeficiency virus (HIV-1) infection in treatment-experienced adult patients with evidence of HIV-1 replication despite ongoing antiretroviral therapy.",

author = "D. Hughes and D.A. Hughes and \{All Wales Strategy Group.\}, \{[No Value]\}",

year = "2008",

month = jan,

day = "1",

language = "English",

publisher = "Unknown",

edition = "2008",

}

Hughes, D, Hughes, DA & All Wales Strategy Group., NV 2008, All Wales Medicines Strategy Group Final Appraisal Report - Raltegravir (Isentress) in combination with other antiretroviral medicinal products for the treatment of human immunodeficiency virus (HIV-1) infection in treatment-experienced adult patients with evidence of HIV-1 replication despite ongoing antiretroviral therapy. 2008 edn, Unknown.

All Wales Medicines Strategy Group Final Appraisal Report - Raltegravir (Isentress) in combination with other antiretroviral medicinal products for the treatment of human immunodeficiency virus (HIV-1) infection in treatment-experienced adult patients with evidence of HIV-1 replication despite ongoing antiretroviral therapy. / Hughes, D.; Hughes, D.A.; All Wales Strategy Group., [No Value].
2008 ed. Unknown, 2008.

Research output: Book/Report › Commissioned report

TY - BOOK

T1 - All Wales Medicines Strategy Group Final Appraisal Report - Raltegravir (Isentress) in combination with other antiretroviral medicinal products for the treatment of human immunodeficiency virus (HIV-1) infection in treatment-experienced adult patients with evidence of HIV-1 replication despite ongoing antiretroviral therapy.

AU - Hughes, D.

AU - Hughes, D.A.

AU - All Wales Strategy Group., [No Value]

PY - 2008/1/1

Y1 - 2008/1/1

UR - http://www.wales.nhs.uk/sites3/Documents/371/Raltegravir%20(Isentress)%20FAR%20Final%20For%20Website.pdf

M3 - Commissioned report

BT - All Wales Medicines Strategy Group Final Appraisal Report - Raltegravir (Isentress) in combination with other antiretroviral medicinal products for the treatment of human immunodeficiency virus (HIV-1) infection in treatment-experienced adult patients with evidence of HIV-1 replication despite ongoing antiretroviral therapy.

PB - Unknown

ER -

Hughes D, Hughes DA, All Wales Strategy Group. NV. All Wales Medicines Strategy Group Final Appraisal Report - Raltegravir (Isentress) in combination with other antiretroviral medicinal products for the treatment of human immunodeficiency virus (HIV-1) infection in treatment-experienced adult patients with evidence of HIV-1 replication despite ongoing antiretroviral therapy. 2008 ed. Unknown, 2008.

UN SDGs

Other files and links

Cite this